A study in the Journal of Headache and Pain found hormone-related factors and premenstrual syndrome may affect migraine intensity during pregnancy but not frequency of headaches. "We suggest that an individual treatment plan for migraines during pregnancy is needed especially for those women with the highest symptoms load," researchers said.
Combining education about pain neuroscience with exercise that used movements patients feared or avoided was better than current physiotherapy best practices and led to a 50% improvement in chronic back and neck pain, researchers reported in JAMA Neurology. The improvements lasted for one year and likely were due to "integrating the newly derived pain neuroscience understanding in specific fearful movements and activities, enabling patients to deal with pain in daily life."
Injectable erenumab, an experimental drug that blocks a brain "neurotransmitter" chemical linked to pain signals, may prevent migraines in patients who do not respond to other therapies, according to a study to be presented at the American Academy of Neurology's annual meeting. Researchers said the drug reduced the average number of monthly migraines by more than 50% for 30% of patients.
A study reported in JAMA Psychiatry found the US is seeing a decline in the prescription of both opioids and benzodiazepines, addressing a mix of medications that the NIH reports is a significant factor in opioid overdose deaths. Researchers found that in 2015, patients using benzodiazepines were twice as likely to be prescribed opioids as those not using benzodiazepines, down from nearly fourfold in 2010.
The Joint Commission will accept comments until May 22 on new standards proposed for assessing and managing pain in office-based surgery settings and ambulatory settings. The changes are aimed at making safe opioid prescribing a priority within health care practices and reducing the risks related to pain management.
The American Society of Addiction Medicine and the American Medical Association have proposed an alternative way of paying health care providers who treat patients with opioid abuse disorder, arguing the current reimbursement model does not include all services patients need to fully recover. Under the proposed model, providers would receive an initial one-time payment to cover the costs related to assessment, diagnosis and planning treatment for a patient, as well as a month of outpatient medication-assisted therapy, which would be followed by monthly maintenance payments to cover the costs of ongoing outpatient medication-assisted treatment, psychological care and social services.
The Scientific Summit sessions are available for purchase. The online recording is a valuable reference comprising 26.5 hours of synchronized audio recordings and slides of educational sessions, SIG meetings and presentations by award recipients at the 2018 Scientific Summit in Anaheim, Calif. Full meeting Summit attendees have access to the recordings in their online account. Learn more.
What's on tap for 2019?
Mark your calendars for the 2019 APS Scientific Meeting on April 3-6 in Milwaukee, Wis. The APS annual meeting is the forum for clinicians, researchers, nurses, psychologists, pharmacists and other health care professionals. Meet with leaders in the pain community who are translating research into relief, take advantage of continuing education credits, and gain insight on important topics in pain science.
If you reject the food, ignore the customs, fear the religion and avoid the people, you might better stay home.